epigallocatechin gallate has been researched along with semaxinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banik, NL; Karmakar, S; Mohan, N; Ray, SK | 1 |
| Chen, CY; Lan, SJ; Lan, YH; Lin, YJ; Sheu, MJ; Wang, CCN | 1 |
2 other study(ies) available for epigallocatechin gallate and semaxinib
| Article | Year |
|---|---|
SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.
Topics: Angiogenesis Inhibitors; Anticarcinogenic Agents; Apoptosis; Catechin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; E2F1 Transcription Factor; Humans; In Situ Nick-End Labeling; Indoles; Neovascularization, Pathologic; Neuroblastoma; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Retinoblastoma Protein; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Epigallocatechin-3-gallate inhibits tumor angiogenesis: involvement of endoglin/Smad1 signaling in human umbilical vein endothelium cells.
Topics: Angiogenesis Inhibitors; Catechin; Cell Movement; Cell Proliferation; Cells, Cultured; Endoglin; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrroles; Signal Transduction; Smad1 Protein; Vascular Endothelial Growth Factor A | 2019 |